دورية أكاديمية

Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis

التفاصيل البيبلوغرافية
العنوان: Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis
المؤلفون: Tanaka, Kenji, Sakasai-Sakai, Akiko, Motomiya, Yasuki, Yoneda, Tatsuo, Takeuchi, Masayoshi
المصدر: Diabetology & Metabolic Syndrome ; volume 13, issue 1 ; ISSN 1758-5996
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2021
مصطلحات موضوعية: Endocrinology, Diabetes and Metabolism, Internal Medicine
الوصف: Background 1,5-anhydroglucitol is a reduction product of 1,5-anhydrofructose. Circulating 1,5-anhydroglucitol is usually excreted by the kidneys and is reabsorbed via sodium-glucose co-transporter 4 in the renal tubules. In patients on hemodialysis, serum levels of 1,5-anhydroglucitol have been reported to be low; however, the underlying mechanism remains unclear. Methods We measured inter-dialysis changes in the levels of serum 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products (AGEs) in 78 patients on hemodialysis. Serum levels of 1,5-anhydrofructose-derived AGEs were also determined using a polyclonal antibody. Results The serum 1,5-anhydroglucitol level was decreased to as low as 2.0 μg/mL in the regular hemodialysis group; however, we could not verify changes in the serum 1,5-anhydroglucitol level during inter-dialysis days because of undetectable levels in 29 patients. The measured serum level of 1,5-anhydrofructose-derived AGEs was significantly increased in both patient groups. In addition, the 1,5-anhydrofructose-derived AGEs/1,5-anhydroglucitol ratio was higher in patients on hemodialysis than in controls. Conclusions Accelerated glycation of 1,5-anhydrofructose is one possible mechanism by which serum 1,5-anhydroglucitol levels are lowered in patients on HD, and we propose that the 1,5-anhydrofructose-derived AGEs/1,5-anhydroglucitol ratio should be measured in clinical settings in which patients have low serum levels of 1,5-AG.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1186/s13098-021-00685-w
DOI: 10.1186/s13098-021-00685-w.pdf
DOI: 10.1186/s13098-021-00685-w/fulltext.html
الإتاحة: https://doi.org/10.1186/s13098-021-00685-wTest
حقوق: https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test
رقم الانضمام: edsbas.DC57E8BD
قاعدة البيانات: BASE